Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for Pain Modulation in Psoriatic Arthritis
NCT06974474Phase 4Recruiting
- Sponsor
- Fondazione Policlinico Universitario Campus Bio-Medico
- Start
- Jun 2024
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of guselkumab in psoriatic arthritis (PsA), sponsored by Fondazione Policlinico Universitario Campus Bio-Medico. Started Jun 2024; status: recruiting.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06974474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06974474.